Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 14/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14546468 | 0.83 | ALDH1A1 (0.44) | HDAC2HDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6034749 | 0.82 | HDAC1 (0.44) | HDAC2HDAC1 | |
| SCHEMBL14857367 | 0.82 | HPGD (0.53) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL24378432 | 0.80 | HDAC1 (0.48) | HDAC2HDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18148233 | 0.80 | ALDH1A1 (0.47) | HDAC2HDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21954020 | 0.80 | ALDH1A1 (0.48) | HDAC2HDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10031015 | 0.79 | HPGD (0.51) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL18510178 | 0.79 | HPGD (0.51) | ALDH1A1SMN1; SMN2 | |
| Hexanoate SCHEMBL8504664 | 0.78 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL19188184 | 0.78 | HDAC1 (0.47) | HDAC2HDAC1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788760-A2 | RECOMBINANT DEAMIDATED GLIADIN ANTIGEN | Bio-rad Laboratories, Inc. (US) | 2014-10-15 | — | — | EP | claimed |
| WO-2013085851-A2 | RECOMBINANT DEAMIDATED GLIADIN ANTIGEN | BIO-RAD LABORATORIES, INC. (US) | 2013-06-13 | — | — | WO | claimed |
| US-12618071-B2 | Multimeric oligonucleotides with divided strands | MPEG LA, L.L.C. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260103629-A1 | COMPOSITIONS OF WET ADHESIVES DERIVED FROM VIBRIO CHOLERAE BIOFILM ADHESINS AND METHODS THEREOF | UNIV YALE (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260071003-A1 | COMPOSITIONS AND METHODS FOR DIRECTING APOLIPOPROTEIN L1 TO INDUCE MAMMALIAN CELL DEATH | UNIV GEORGIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-12435158-B2 | Anti-lambda myeloma antigen (LMA) binding proteins to treat LMA-expressing cancer and autoimmune disorders | HaemaLogiX Ltd (AU) | 2025-10-07 | — | — | US | disclosed |
| US-12378551-B2 | Multimeric oligonucleotides having decreased kidney clearance | MPEG LA, L.L.C. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12312417-B2 | Binding proteins 1 | Nucleus Therapeutics Pty. Ltd. (AU) | 2025-05-27 | — | — | US | disclosed |
| US-20250163144-A1 | ENGINEERED VLRB ANTIBODIES WITH IMMUNE EFFECTOR FUNCTIONS | NOVAB, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4541374-A2 | DEFINED MULTI-CONJUGATE OLIGONUCLEOTIDES | Mpeg LA, L.l.c. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20240368259-A1 | ANTIBODIES AGAINST LEFTY PROTEINS | Onena Medicines, S.L. (ES) | 2024-11-07 | — | — | US | disclosed |
| EP-2594583-A1 | Transferrin variants and conugates | Novozymes Biopharma DK A/S (DK) | 2013-05-22 | — | — | EP | disclosed |
| US-8445637-B2 | SPARC binding peptides and uses thereof | ABRAXIS BIOSCIENCE, LLC (US) | 2013-05-21 | — | — | US | disclosed |
| WO-2012045063-A2 | FLAVIVIRUS DOMAIN III VACCINE | UNIVERSITY OF ROCHESTER (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20110313133-A1 | Albumin variants and conjugates | NOVOZYMES A/S (DK) | 2011-12-22 | — | — | US | disclosed |
| EP-2396347-A2 | ALBUMIN VARIANTS AND CONJUGATES | Novozymes Biopharma DK A/S (DK) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092135-A2 | ALBUMIN VARIANTS AND CONJUGATES | NOVOZYMES BIOPHARMA UK LTD. (GB) | 2010-08-19 | — | — | WO | disclosed |
| EP-2201036-A1 | TRANSFERRIN VARIANTS AND CONJUGATES | Novozymes Biopharma DK A/S (DK) | 2010-06-30 | — | — | EP | disclosed |
| WO-2010065950-A2 | ALBUMIN BINDING PEPTIDE-MEDIATED DISEASE TARGETING | ABRAXIS BIOSCIENCE, LLC (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2009019314-A1 | TRANSFERRIN VARIANTS AND CONJUGATES | NOVOZYMES A/S (DK) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103629-A1 | COMPOSITIONS OF WET ADHESIVES DERIVED FROM VIBRIO CHOLERAE BIOFILM ADHESINS AND METHODS THEREOF | VCL, VCAM1, BAP1 | HDAC2 4834/4885HDAC1 4286/4885NOD1 1040/4885 |
| US-20250163144-A1 | ENGINEERED VLRB ANTIBODIES WITH IMMUNE EFFECTOR FUNCTIONS | VSIR, FCGR2A, FCGR3B | HDAC2 3825/4885HDAC1 3732/4885NOD1 506/4885 |
| US-20260071003-A1 | COMPOSITIONS AND METHODS FOR DIRECTING APOLIPOPROTEIN L1 TO INDUCE MAMMALIAN CELL DEATH | APOL1, APOB, LY96 | HDAC2 4700/4885HDAC1 4471/4885NOD1 2044/4885 |
| US-12378551-B2 | Multimeric oligonucleotides having decreased kidney clearance | DCLRE1B, ATP6V1B1, MTX1 | HDAC2 4829/4885HDAC1 4549/4885NOD1 2307/4885 |
| US-12618071-B2 | Multimeric oligonucleotides with divided strands | DCLRE1B, MICA, LIG1 | HDAC2 4711/4885HDAC1 4728/4885NOD1 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.